Q2 EPS Forecast for Spruce Biosciences Boosted by Analyst

Spruce Biosciences, Inc. (NASDAQ:SPRB) – Analysts at HC Wainwright lifted their Q2 2026 earnings estimates for shares of Spruce Biosciences in a research report issued to clients and investors on Monday, June 1st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($5.69) per share for the quarter, up from their previous estimate of ($8.20). HC Wainwright has a “Buy” rating and a $150.00 price target on the stock. The consensus estimate for Spruce Biosciences’ current full-year earnings is ($27.49) per share. HC Wainwright also issued estimates for Spruce Biosciences’ Q3 2026 earnings at ($4.81) EPS, Q4 2026 earnings at ($4.58) EPS, FY2026 earnings at ($22.16) EPS and FY2027 earnings at ($9.09) EPS.

A number of other analysts have also issued reports on SPRB. Oppenheimer reissued an “outperform” rating on shares of Spruce Biosciences in a research report on Wednesday, May 27th. Citizens Jmp dropped their price objective on Spruce Biosciences from $170.00 to $150.00 and set a “market outperform” rating for the company in a research note on Thursday, May 14th. Finally, Craig Hallum began coverage on Spruce Biosciences in a report on Monday, April 27th. They issued a “buy” rating and a $140.00 price objective on the stock. Five analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Spruce Biosciences presently has an average rating of “Moderate Buy” and an average target price of $176.60.

Spruce Biosciences Stock Performance

Shares of SPRB stock opened at $49.30 on Wednesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.67 and a current ratio of 4.67. The firm has a market cap of $135.58 million, a P/E ratio of -1.35 and a beta of 3.11. The firm’s 50 day moving average price is $59.11 and its 200-day moving average price is $71.89. Spruce Biosciences has a one year low of $4.35 and a one year high of $240.00.

Spruce Biosciences (NASDAQ:SPRB) last announced its earnings results on Wednesday, May 13th. The company reported ($8.94) earnings per share for the quarter, missing the consensus estimate of ($7.93) by ($1.01).

Institutional Investors Weigh In On Spruce Biosciences

Several large investors have recently added to or reduced their stakes in SPRB. Cable Car Capital LP acquired a new stake in Spruce Biosciences during the 3rd quarter worth approximately $239,000. SkyView Investment Advisors LLC acquired a new position in shares of Spruce Biosciences in the fourth quarter worth $261,000. Stempoint Capital LP purchased a new stake in shares of Spruce Biosciences during the first quarter worth $416,000. State Street Corp purchased a new stake in shares of Spruce Biosciences during the fourth quarter worth $558,000. Finally, Superstring Capital Management LP acquired a new stake in shares of Spruce Biosciences in the fourth quarter valued at $1,057,000. 91.71% of the stock is owned by hedge funds and other institutional investors.

About Spruce Biosciences

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.